INTRODUCTION
18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET)-based assessment of the myocardium is useful in the evaluation of primary cardiac tumors or cardiac metastasis, to examine the viability following myocardial ischemia and for the detection of inflammatory myocardial sarcoid lesions. However, because the cardiac FDG uptake shows several different patterns in the fasting state, it is often difficult to distinguish between normal or abnormal uptake. Therefore, it is recommended that glucose loading should be performed to increase this uptake prior to estimating the viability. In addition, heparin loading is carried out to suppress the physiological uptake of FDG in the myocardium before
ORIGINAL
The physiological uptake pattern of 18 F-FDG in the left ventricular myocardium of patients without heart disease attempting the detection of inflammatory lesions, such as sarcoidosis.
In Japan, the use of 18 F-FDG PET was approved by the national health insurance program for evaluating cardiac sarcoidosis in 2012. It is therefore speculated that the number of 18 F-FDG PET examinations for cardiac sarcoidosis will increase. However, the normal heart frequently shows physiological uptake, and the physiological uptake is different for each patient, and may even differ within individual patients during different examinations. Therefore, it is often difficult to evaluate whether the uptake is abnormal or not.
In the present study, we evaluated the physiological cardiac accumulation of FDG under preparation for tumor FDG-PET.
METHODS AND MATERIALS
This retrospective study was approved by the institutional review board of Tokushima University Hospital.
A total of 207 consecutive outpatients who underwent FDG-PET/CT for tumor imaging between March 30, 2011 and May 13, 2011 at our hospital were enrolled in this study. The suspected diseases for which FDG PET/CT was used are shown in Table 1 . Nineteen patients were excluded for the following reasons : 11 had cardiac disease (four cases of angina, four of arrhythmia, one old myocardial infarction, one congestive heart failure and one had undergone pericardiectomy), seven patients (four with esophageal cancer, three with lung cancer) had undergone radiation therapy during which the heart was included in the irradiated field ; and one patient had very poor imaging data due to obesity. Therefore, we investigated a total of 188 patients (84 males and 104 females ; mean age, 64.1 years ; and age range, 27-90 years).
FDG PET/CT
All patients prepared for the examination by fasting for at least six hours prior to tumor PET imaging. After verification of their blood glucose level, the patients were intravenously injected with 128-290 MBq/kg of FDG. Patients were then examined using a PET/CT scanner (Auiduo : Toshiba Medical Systems Corporation, Tochigi, Japan) one hour after FDG injection. Image acquisition was performed from the top of the head to the middle of the thigh. The attenuation-corrected PET images, non-attenuation-corrected PET images and CT images were reviewed, and the attenuation-corrected PET and CT images were co-registered using a commercial software program (Aquarius NET Viewer : TeraRecon Inc, San Mateo, CA, USA). Lung lesion 28 cancer (3) cancer (21) other (1) others (7 
Analysis of the FDG PET images
The FDG uptake in the myocardium was classified into four patterns as described in two previous reports (1, 2) : 'none', 'diffuse', 'focal' and 'focal on diffuse' (Figure 1) . The "none" pattern indicated no uptake of FDG in the myocardium or less uptake than was observed in the mediastinum. The "diffuse" pattern indicated a diffuse and homogeneous uptake of FDG in the left ventricle (LV) wall. The pattern was only classified as "focal" when a focal uptake was observed. The "focal on diffuse" pattern indicated a focal uptake overlying the diffuse pattern. However, if a focal nodular uptake was only seen in the lateral wall of the LV, we did not classify the pattern as a "focal" or "focal on diffuse" pattern, because normal papillary muscle often shows a focal uptake in the lateral wall. When the "focal" or "focal on diffuse" patterns were seen, we further classified these focal FDG uptake patterns into three additional patterns when it was only observed in the basal wall (Figure 2 ). These three patterns were the 'ring' pattern, 'over half' pattern and 'spot' pattern. The 'ring' pattern was characterized by a diffuse accumulation of FDG in the basal wall, the 'over half' pattern showed more than 50% accumulation, and the 'spot' pattern showed less than 50% accumulation. Two or three board-certified radiologists, who were blinded to all of the clinical information, performed the visual analysis and classified the uptake patterns.
Statistical analysis
The differences between the uptake patterns based on the age, blood glucose level and weight were evaluated using the Tukey test. A value of p! 0.05 was considered to be statistically significant.
RESULTS
The frequencies of the myocardial FDG uptake patterns were as follows : "none", n=52 (27.7%) ; "diffuse", n=63 (33.5%) ; "focal on diffuse", n=40 (21.3%) and "focal", n=33 (17.6%) ( Table 2 ). The age, blood glucose level, weight and dose of FDG did not differ significantly (p"0.05) for each pattern (Table 3) . The "focal" and "focal on diffuse" patterns were seen in 73 patients, and 65 of these patients exhibited focal uptake of FDG in the basal wall only ('ring', n=29 ; 'over half', n=20 and 'spot', n=16) (Table 4) . Patients with a "focal on diffuse" pattern did not have a 'spot' pattern, and only one patient had a "focal" pattern with a 'ring' pattern. Eight patients had focal uptake in other regions (apex, n=4 ; lateral, n=3 and anterior, n=1).
DISCUSSION
The myocardium metabolizes fatty acids and glucose as energy sources. With sufficiently extended fasting, the myocardium shifts from a predominantly glycolytic metabolism to a fatty acid metabolism (3). In the clinical oncology setting, FDG PET is usually performed on patients who have been fasting for about six hours, so the fatty acid metabolism will be predominant over the glucose metabolism. However, cardiac FDG uptake often shows several patterns in the fasting state, and even in the same patient, the uptake can show different patterns at different times. There have been some previous reports on the physiological cardiac FDG uptake (4) (5) (6) (7) (8) . In these reports, it was stated that the cardiac uptake showed various patterns, but that parameters such as the patient age, blood glucose level, weight and dose of FDG were not related to the uptake patterns in the myocardium. The myocardial metabolic rate is relative to the serum free fatty acid levels, but it does not depend only on the fasting period. In line with these findings, it was found in our study that the cardiac FDG uptake showed various patterns, but no parameters had a significant effect on these patterns.
Patients with cardiac disease, such as sarcoidosis (1, 2, 9-12), pulmonary hypertension (13), hypertrophic cardiomyopathy (14-16), a tumor or damage to the myocardium caused by radiotherapy (17) (18) (19) (20) (21) show abnormally high accumulation of FDG. In addition, cardiac sarcoidosis shows focal uptake (1, 2). We also investigated patients who showed focal FDG uptake. Thirty-three patients (17.6%) exhibited a "focal" pattern and 40 (21.3%) exhibited a "focal on diffuse" pattern. A total of 73 patients (38.8%) showed focal uptake. Thus, cardiac focal uptake was frequently seen in patients without cardiac disease. However, almost all of these patients (65/73, 89.0%) accumulated FDG only in the basal wall, which showed various patterns and degrees of focal uptake. Therefore, the uptake in the basal wall did not always indicate an abnormal finding when an examination was undertaken in the fasting state. However, patients without cardiac disease rarely show focal uptake of FDG in other regions. In our study, only eight of the 185 (4.3%) patients exhibited focal uptake in another region. If we decided that the focal uptake of FDG in the basal wall was normal, and focal uptake in another region was abnormal, the accuracy and specificity increased, but the sensitivity decreased, and we could not determine the true level of abnormal uptake in the basal wall.
Heparin increases the serum free fatty acid levels, reduces saccharometabolism and possibly minimizes the background myocardial uptake of FDG. Heparin also activates plasma lipoprotein lipase, which separates fatty acids. It is difficult to evaluate the cardiac uptake in the fasting state, so heparin loading should be carried out before injecting FDG. None of the differences were statistically significant (p!0.05)
When heparin loading is performed in patients without cardiac disease, the cardiac FDG uptake showed either the "none" pattern or the "diffuse" pattern, so we can easily evaluate the cardiac uptake. It is useful to use cardiac MRI or blood-flow scintigraphy in combination with this approach. A major limitation of our study is that we labeled some patients as having no cardiac disease on the basis of only the clinical symptoms and anamnesis, so it could not be definitely confirmed that all of the enrolled patients were free from cardiac disease.
CONCLUSIONS
The physiological myocardial FDG uptake followed several patterns and frequently involved a focal uptake. Therefore, a focal uptake was often seen in patients with some cardiac diseases. However, this uptake did not necessarily indicate abnormal findings when the FDG accumulation only occurred in the basal wall. We should therefore be aware of the physiological uptake pattern when PET examinations are performed on patients in a fasting state.
